IRIS
BLANDINI, FABIO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.350
EU - Europa 1.810
AS - Asia 695
AF - Africa 17
OC - Oceania 8
SA - Sud America 5
Continente sconosciuto - Info sul continente non disponibili 3
Totale 5.888
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.307
IE - Irlanda 971
CN - Cina 669
FI - Finlandia 207
UA - Ucraina 193
DE - Germania 156
IT - Italia 104
SE - Svezia 66
GB - Regno Unito 49
CA - Canada 43
FR - Francia 27
BE - Belgio 23
MU - Mauritius 14
AU - Australia 7
TR - Turchia 7
SA - Arabia Saudita 5
IN - India 4
RU - Federazione Russa 4
EU - Europa 3
HK - Hong Kong 3
PL - Polonia 3
BR - Brasile 2
JP - Giappone 2
AL - Albania 1
AM - Armenia 1
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
EC - Ecuador 1
EG - Egitto 1
ES - Italia 1
ID - Indonesia 1
KW - Kuwait 1
LU - Lussemburgo 1
LV - Lettonia 1
MY - Malesia 1
NG - Nigeria 1
NL - Olanda 1
NZ - Nuova Zelanda 1
PE - Perù 1
VN - Vietnam 1
ZA - Sudafrica 1
Totale 5.888
Salva come PNG Salva come JPEG
Città #
Chandler 1.008
Dublin 971
Ashburn 316
Jacksonville 251
Princeton 190
Lawrence 186
Nanjing 176
Medford 152
Wilmington 136
Helsinki 101
Nanchang 77
Shenyang 66
Beijing 59
Changsha 53
Shanghai 47
Hebei 45
New York 45
Ann Arbor 43
Jiaxing 42
Toronto 39
Pavia 33
Tianjin 32
Norwalk 31
Boardman 29
Hangzhou 28
Washington 26
Brussels 23
Milan 17
San Francisco 17
Fairfield 14
Los Angeles 14
Woodbridge 14
Des Moines 10
Philadelphia 10
Seattle 9
Verona 7
Jinan 6
Paris 5
Rome 5
Berlin 4
Falls Church 4
Giessen 4
Kunming 4
Southend 4
Wuhan 4
Zhengzhou 4
Asti 3
Borås 3
Canberra 3
Dearborn 3
Guangzhou 3
Ningbo 3
Riyadh 3
Warsaw 3
Atlanta 2
Auburn Hills 2
Central 2
Changchun 2
Houston 2
Lanzhou 2
London 2
Melbourne 2
Newark 2
Olympia 2
Orange 2
Ostiglia 2
Petilia Policastro 2
Reggio Nell'emilia 2
Salford 2
São Paulo 2
Taizhou 2
Tappahannock 2
Abuja 1
Almere Stad 1
Andover 1
Auckland 1
Böblingen 1
Cairo 1
Cambridge 1
Centurion 1
Cinisello Balsamo 1
Cologne 1
Edmonton 1
Esslingen am Neckar 1
Falkenstein 1
Fuzhou 1
Gunzenhausen 1
Haikou 1
Hanoi 1
Harrington 1
Hyderabad 1
Izmir 1
Jakarta 1
Jeddah 1
Kemerovo 1
Kofu 1
Krasnoyarsk 1
Kuwait City 1
L'aquila 1
Leawood 1
Totale 4.449
Salva come PNG Salva come JPEG
Nome #
Correlation of LTP and LTD with gene expression in the cerebellar cortex. 91
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model 85
Immediate early genes regulation in rat cerebellar cortex during long-term synaptic plasticity induction. 74
Stress and Autonomic Nervous System 72
Long-term synaptic plasticity and related gene expression in the cerebellar cortex. 66
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 65
Aging and dementia: markers of the hypothalamus-pituitary-adrenal axis and sympathetic activities in biological fluids 62
Alterazioni neurochimiche del sistema nervoso enterico (SNE) in un modello sperimentale di Parkinson 62
The role of dopamine in the modulation of gastrointestinal motility in a rat model of Parkinson's disease 62
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease. 60
Functional changes of the basal ganglia circuitry in Parkinson's disease. 60
A new 5-HT2 antagonist (ritanserin) in the treatment of chronic headache with depression. A double-blind study vs amitriptyline. 60
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 60
Nitroglycerin-induced activation of monoaminergic trasmission in the rat 58
Selective blockade of mGlu5 metabotropic glutamate receptors is protective against hepatic mitochondrial dysfunction in 6-OHDA lesioned Parkinsonian rats 58
Activation of the CREB/c-Fos Pathway during Long-Term Synaptic Plasticity in the Cerebellum Granular Layer 58
Impaired hepatic function and central dopaminergic denervation in a rodent model of Parkinson's disease: a self perpetuating crosstalk? 56
Oxidative stress and pro-apoptotic conditions in a rodent model of Wilson's disease. 55
Functional and neurochemical changes of the gastrointestinal tract in a rodent model of Parkinson's disease. 55
Effects of dopaminergic stimulation on peripheral markers of apoptosis: relevance to Parkinson's disease. 55
Effects of the intrastriatal administration of selective dopaminergic agonists on Fos expression in the rat brain. 55
Acute Reduction of Anandamide-Hydrolase (FAAH) Activity is Coupled With a Reduction of Nociceptive Pathways Facilitation in Medication-Overuse Headache Subjects After Withdrawal Treatment. 55
From drug-induced headache to medication overuse headache. A short epidemiological review, with a focus on Latin American countries 54
Valutazione delle catecolamine plasmatiche: influenza di fattori ambientali e delle procedure di campionamento 53
Immediate early genes expression in the cerebellar cortex correlates with LTP and LTD induction. 53
Peripheral levels of BDNF and NGF in primary headaches 53
Endothelial nitric oxide synthase inhibition triggers inflammatory responses in the brain of male rats exposed to ischemia-reperfusion injury 53
Homocysteine and Parkinson's disease: a dangerous liaison? 51
Modulation of noradrenergic activity by magnesium salts in panic disorder and neuronal hyperexcitability syndrome 51
Response of colonic motility to dopaminergic stimulation is subverted in rats with nigrostriatal lesion: Relevance to gastrointestinal dysfunctions in Parkinson's disease 51
Modulation of RAGE isoforms expression in the brain and plasma of rats exposed to transient focal cerebral ischemia. 50
Intestinal dysmotility and enteric neurochemical changes in a Parkinson's disease rat model. 49
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 49
Free plasma catecholamine levels in healthy subjects: a basal and dynamic study 48
Unilateral lesion of the subthalamic nucleus enhances cortical fos expression associated with focally evoked seizures in the rat 47
Modifications of apoptosis-related protein levels in lymphocytes of patients with Parkinson's disease. The effect of dopaminergic treatment. 47
Movement disorders and aging. 45
Systemic administration of ephedrine induces Fos protein expression in caudate putamen and subthalamic nucleus of rats. 45
Intestinal dysmotility and enteric neurochemical changes following nigrostriatal dopaminergic denervation in the rat: relevance to the gastrointestinal dysfunction associated with Parkinson's disease 44
Behavioral responses and Fos activation following painful stimuli in a rodent model of Parkinson's disease 44
Selective lesion of the substantia nigra pars reticulata reduces the cortical Fos expression induced by stimulation of striatal D1-like receptors, in the rat 44
Modifications of neuroactive steroid levels in an experimental model of nigrostriatal degeneration: Potential relevance to the pathophysiology of Parkinson's disease 44
Effects of CGRP receptor antagonism in nitroglycerin-induced hyperalgesia. 43
Alteration of colonic excitatory tachykininergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 42
Gba mutations influence the release and pathological effects of small extracellular vesicles from fibroblasts of patients with parkinson’s disease 42
Variabilita' delle risposte adattative a stimoli stressanti nell'uomo in rapporto all'eta'. 41
Nitroglycerin enhances cGMP expression in specific neuronal and cerebrovascular structures of the rat brain 40
Naproxen Sodium in Menstrual Migraine Prophylaxis: A Double‐Blind Placebo Controlled Study 40
The influence of gender in the evaluation of platelet and plasma catecholamines 39
Noninvasive near-infrared live imaging of human adult mesenchymal stem cells transplanted in a rodent model of Parkinson's disease 39
Effects of L-DOPA/benserazide co-treatment on colonic excitatory cholinergic motility and enteric inflammation following dopaminergic nigrostriatal neurodegeneration 38
Assay of [3H] dihydrorotenone binding to complex I in intact human platelets 38
Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells 38
Cerebrospinal fluid norepinephrine, 3 -methoxy 4 -hydroxyphenylglicol and neuropeptide Y levels in dementia of the Alzheimer type 37
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 37
Effect of nitric oxide donors on the central nervous system--nitroglycerin studies in the rat. 37
Adenosine receptors and L-DOPA-induced dyskinesia in Parkinson's disease: Potential targets for a new therapeutic approach 37
Radiological analysis of gastrointestinal dysmotility in a model of central nervous dopaminergic degeneration: Comparative study with conventional in vivo techniques in the rat 37
Repurposing opportunities for Parkinson’s disease therapies 37
Inefficient DNA Repair Is an Aging-Related Modifier of Parkinson's Disease 37
Parkinson's disease patients have a complex phenotypic and functional Th1 bias: Cross-sectional studies of CD4+ Th1/Th2/T17 and Treg in drug-naïve and drug-treated patients 36
In vivo imaging of early signs of dopaminergic neuronal death in an animal model of Parkinson's disease 36
Potential therapeutic effects of polyphenols in Parkinson's disease: In vivo and in vitro pre-clinical studies 36
Prospects of glutamate antagonists in the therapy of Parkinson's disease 36
Adhesion molecules as potential targets for neuroprotection in a rodent model of Parkinson's disease 36
A 2A receptor antagonism and dyskinesia in parkinson's disease 36
Pro-oxidant activity and methionine metabolism in chronic alcohol abusers: relationship to alcohol withdrawal and folate administration 36
Neuroprotective effects of human mesenchymal stem cells on neural cultures exposed to 6-hydroxydopamine: Implications for reparative therapy in Parkinson's disease 35
Intracarotid infusion of mesenchymal stem cells in an animal model of Parkinson’s disease, focusing on cell distribution and neuroprotective and behavioral effects 35
Activation of the DNA damage response in vivo in synucleinopathy models of Parkinson’s disease 35
Neuroprotective potential of adenosine A2A and cannabinoid CB1 receptor antagonists in an animal model of Parkinson disease 35
Plasma beta-endorphin, cortisol and norepinephrine responses to physical and metabolic stressors in young and elderly humans. 34
Proteasomal inhibition and apoptosis regulatory changes in human isolated lymphocytes: The synergistic role of dopamine 34
Neuroprotection by rasagiline: A new therapeutic approach to Parkinson's disease? 34
Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia 33
Role of central dopaminergic circuitry in pain processing and nitroglycerin-induced hyperalgesia 33
Complex Changes in the Innate and Adaptive Immunity Accompany Progressive Degeneration of the Nigrostriatal Pathway Induced by Intrastriatal Injection of 6-Hydroxydopamine in the Rat 33
Development and biochemical characterization of a mouse model of Parkinson's disease bearing defective glucocerebrosidase activity 33
Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease 33
Neuroprotection by the PARP inhibitor PJ34 modulates cerebral and circulating RAGE levels in rats exposed to focal brain ischemia. 32
The exosomal/total α-synuclein ratio in plasma is associated with glucocerebrosidase activity and correlates with measures of disease severity in PD patients 32
Fibroblasts from skin biopsies as a tool for biomarker discovery in Parkinson׳s disease 32
A further update on the role of excitotoxicity in the pathogenesis of Parkinson’s disease 32
Dietary restriction does not prevent nigrostriatal degeneration in the 6-hydroxydopamine model of Parkinson's disease 32
The 6-hydroxydopamine model: News from the past 32
Toxic profile of bergamot essential oil on survival and proliferation of SH-SY5Y neuroblastoma cells 32
Bioenergetic and proteolytic defects in fibroblasts from patients with sporadic Parkinson's disease 32
Glucocerebrosidase mutations and synucleinopathies: Toward a model of precision medicine 31
Dual target strategy: Combining distinct non-dopaminergic treatments reduces neuronal cell loss and synergistically modulates l -DOPA-induced rotational behavior in a rodent model of Parkinson's disease 31
DNA fragmentation and oxidative stress in the hippocampal formation: A bridge between 3,4-methylenedioxymethamphetamine (ecstasy) intake and long-lasting behavioral alterations 31
Electrophysiological and metabolic effects of CHF5074 in the hippocampus: Protection against in vitro ischemia 31
Animal models of Parkinson's disease 31
Evolution of prodromal parkinsonian features in a cohort of GBA mutation-positive individuals: A 6-year longitudinal study 31
Clinical and Dopamine Transporter Imaging Trajectories in a Cohort of Parkinson's Disease Patients with GBA Mutations 31
Modulation of cerebral RAGE expression following nitric oxide synthase inhibition in rats subjected to focal cerebral ischemia 30
Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease 30
Effects of kynurenic acid analogue 1 (KYNA-A1) in nitroglycerin-induced hyperalgesia: Targets and anti-migraine mechanisms 30
The Involvement of Post-Translational Modifications in Alzheimer's Disease 29
Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodent model of Parkinson's disease 29
Cardiopressor effects of short-term treatment with cabergoline in L-Dopa stable responder parkinsonian patients: Relevance of postprandial hypotension 29
Totale 4.367
Salva come PNG Salva come JPEG
Categoria #
all - tutte 27.003
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 27.003
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2018/20197 0 0 0 0 0 0 0 0 0 0 0 7
2019/2020772 232 293 1 38 5 40 9 38 3 58 51 4
2020/2021506 43 34 8 38 1 47 4 69 123 77 53 9
2021/2022816 6 2 34 6 4 16 12 43 51 11 122 509
2022/20232.712 302 199 43 236 218 259 0 165 1.184 9 55 42
2023/2024834 121 146 44 56 92 250 35 56 7 27 0 0
Totale 6.070